Advances in the Diagnosis, Prognosis and Treatment of Diffuse Large B-cell Lymphoma
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 3264
Special Issue Editor
Interests: hematopathology; lymphoma diagnosis; molecular pathology; lymphomagenesis; HIV-related lymphomas
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin (NHL) lymphoma and constitutes 25–35% of adult NHL in developed countries. In recent years, different morphological variants, molecular subtypes, and clinical–biological entities with an impact on prognosis and treatment have been described. However, there is still a group of DLBCL with heterogeneous features, and a better understanding of their biology is necessary for a precise diagnosis, prognostication, and personalized treatment.
In this Special issue, we aim to collect original and review articles focusing on recent advances in the diagnosis, molecular biology, prognostic factors, and management of DLBCL. We hope that this issue will help in further understanding the biology of DLBCL.
You may choose our Joint Special Issue in Cancers.
Dr. Gustavo Tapia
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- no-Hodgkin lymphoma
- diffuse large B-cell lymphoma
- DLBCL
- lymphoma treatment
- lymphoma diagnosis
- lymphoma prognosis
- lymphoma biology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
